The FDA similarly removed it from its shortage list on February 21, 2025, but this time, it designated off-ramps for production of compounded types right off the bat: Technically, 503A pharmacies have until April 22 to quit making semaglutide drugs, while 503B facilities have until May 22
Some observational data suggest that weight loss achieved through any meansincluding GLP-1 medications, bariatric surgery, or lifestyle modificationmay have modest effects on thyroid function tests in individuals with obesity
[14] More recently, the SELECT trial showed that semaglutide 2.4 mg reduced cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity without diabetes
It's also rich in calcium and vitamin D, key nutrients for maintaining strong bones as estrogen levels drop
And they deserve a complete, honest answer that goes beyond a simple yes or no